In a new SEC filing on May 21, it was unveiled that JR, Director at Corcept Therapeutics (NASDAQ:CORT), acquired stock options for 30,000 shares.
What Happened: JR, Director at Corcept Therapeutics, acquired stock options for 30,000 shares of CORT. This information was disclosed in a Form 4 filing with the U.S. Securities and Exchange Commission on Tuesday. The options allow JR to buy the company's stock at $28.09 per share.
The Wednesday morning market activity shows Corcept Therapeutics shares up by 1.01%, trading at $29.09. This implies a total value of $21,300 for JR's 30,000 shares.
All You Need to Know About Corcept Therapeutics
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.
Financial Insights: Corcept Therapeutics
Positive Revenue Trend: Examining Corcept Therapeutics's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 38.95% as of 31 March, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among ...